Browse News
Filter News
Found 156 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin
4/3/2024
ObsEva SA announced that the Regulatory Board of SIX Swiss Exchange has granted the delisting of the shares of the company from SIX Swiss Exchange and has exempted the company from certain obligations associated with the maintenance of the listing.
-
ObsEva Announces Update on Board of Directors - March 19, 2024
3/19/2024
ObsEva SA announced that, concurrent to the decision to wind-down the company’s operations, Catarina Edfjäll, Ph.D. has decided to step down from the Board effective today.
-
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
3/8/2024
XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its fourth quarter and full year 2023 financial results and highlighted portfolio activities expected to drive long-term shareholder value.
-
ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023
2/28/2024
ObsEva SA announced that it will wind-down its operations with the termination of all of its employees, including Fabien de Ladonchamps, CEO, and notified SIX Swiss Exchange's listing authority that there was a substantial risk that it will lack the resources to have financial statements for 2023 prepared under IFRS audited, and that it is as a result likely not going to be able to satisfy the requirements for maintaining its listing on SIX.
-
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals
11/30/2023
ObsEva SA announced that, following a comprehensive assessment of the company's financial position, the Board of Directors has opted to seek a moratorium from the competent court in Geneva, Switzerland.
-
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
11/7/2023
XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its third quarter 2023 financial results.
-
Organon Returns Ebopiprant to XOMA
10/27/2023
ObsEva SA announced that XOMA will be receiving full worldwide rights on ebopiprant, an investigational, orally active, selective prostaglandin F2α receptor antagonist, following the termination of the license agreement with Organon.
-
ObsEva Files half Year 2023 Financial Statements
9/27/2023
ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, published its Half Year 2023 Financial Statements.
-
ObsEva Recovers Full Worldwide Rights on Nolasiban
7/13/2023
ObsEva SA announced that it has recovered full worldwide rights on nolasiban, a novel, oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in women undergoing embryo transfer after in vitro fertilization, following the termination of its sub-licensing agreement with Yuyuan BioScience.
-
Annual General Meeting 2023
6/8/2023
ObsEva SA, a biopharmaceutical company developing novel therapies for women's health, published the invitation to its 2023 Annual General Meeting of Shareholders to be held on June 29, 2023, at 10:30 CEST at the company's offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Switzerland.
-
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer
5/2/2023
ObsEva SA, a biopharmaceutical company developing novel therapies for women’s health, announced that Fabien de Ladonchamps has been appointed Chief Executive Officer effective May 1, 2023.
-
Gameto Expands Executive Team with the Addition of Teri Loxam as Chief Financial Officer
4/28/2023
Gameto, a female-led biotech company developing therapies to improve the female reproductive journey, announced the expansion of its executive team with the appointment of Teri Loxam as its first Chief Financial Officer.
-
ObsEva Announces Change of Central Securities Depositary
4/20/2023
ObsEva SA today announced that it intends for its common shares to be traded under a new International Securities Identification Numbers (“ISIN”) beginning on April 25, 2023.
-
ObsEva Files Year End 2022 Financial Statements
3/31/2023
ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s health, published its U.S. Annual Report on Form 10-K for Fiscal Year 2022, including the U.S. GAAP financial results for year-end 2022.
-
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
3/13/2023
ObsEva SA announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy.
-
XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy
3/9/2023
XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, reported its full year 2022 financial results and provided an operational update on the Company’s actions to accelerate XOMA’s differentiated biotech royalty and milestone acquisition strategy.
-
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
2/24/2023
ObsEva SA announced a strategic reorganization that will consolidate operations in Switzerland so as to preserve cash, focus resources towards the development of nolasiban, a novel, oral oxytocin receptor agonist to improve in vitro fertilization success rates, and manage its out-licensed programs.
-
ObsEva Announces Dismissal of Moratorium Proceedings
12/19/2022
ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced that the competent court in Geneva, Switzerland has granted the Company’s request to withdraw its moratorium considering that the Company is no longer over-indebted.
-
BioSpace Layoff Tracker 2022: Axcella Therapeutics, TherapeuticsMD, Instil Bio and More Cull Staff
12/15/2022
The layoffs trend in the life sciences industry is continuing into the final months of 2022. See inside for details on which companies are reducing staff to increase cash flow.